Identifying “at-risk” patients for sub-optimal beta-lactam exposure in critically ill patients with severe infections

Documenti analoghi

• Continuous beta-lactam infusion in critically ill patients: the clinical evidence
  di: Abdul-Aziz, Mohd H, et al.
  Pubblicazione: (2012)
• Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review
  di: Sime, Fekade Bruck, et al.
  Pubblicazione: (2012)
• Beta-lactam antibiotics in continuous infusion in critically ill patients
  di: Jeurissen, Axel, et al.
  Pubblicazione: (2010)
• We need to optimize piperacillin-tazobactam dosing in critically ill patients—but how?
  di: Cotta, Menino Osbert, et al.
  Pubblicazione: (2016)
• Provider perspectives on beta-lactam therapeutic drug monitoring programs in the critically ill: a protocol for a multicenter mixed-methods study
  di: Barreto, Erin F., et al.
  Pubblicazione: (2021)